Jump to content

R-Pharm

From Wikipedia, the free encyclopedia
R-Pharm logo

R-Pharm (Russian: Р-Фарм) is an international pharmaceutical company headquartered in Russia.[1][2][3][4][5][6] It reached the headlines in September 2020 following approval of its drug "Coronavir" as a treatment in cases of mild to moderate COVID-19 infection.[7][8] It was founded by Alexey Repik (ru) in 2001, but has had an increasingly international operations base since, with Japanese Corporation Mitsui & Co., Ltd. acquiring 10% of its shares in 2017.[9] In 2022, against the background of the introduction of personal sanctions, Alexey Repik resigned from the owners of R-Pharm, selling his share in the company to the management of R-Pharm, and resigned as chairman of the board of directors [1].

Activity

[edit]

The company's scope of activities covers areas related to the development, research, production, marketing of drugs intended primarily for inpatient and specialized medical care.[10] The main areas of activity are: production of finished dosage forms, active pharmaceutical ingredients of chemical nature and biotechnological substances, research and development of drugs and technologies, introduction to the Russian market of pharmaceuticals.[11]

In 2016, R-Pharm supplied 46% of the Russian government contracts and was the largest supplier of pharmaceuticals to the Russian government.[12]

In autumn 2022, Alexei Repik,[a][b] in order to protect R-Pharm from sanctions and to allow lllumina to continue to supply materials to Moscow based Albiogen (Russian: Альбиоген),[c] transferred his share in R-Pharm to management, with Mitsui maintaining a 10% stake which it had acquired in 2017 for $200 million.[19][20]

At the end of 2022, R-Pharm had 162 billion rubles in revenue from the production of medicines for the treatment of autoimmune, oncological, antiviral and other diseases, as well as materials that are used for medical purposes and veterinary medicine.[19]

As of the end of June 2023, R-Pharm had Russia based plants at Yaroslavl, Rostov, Moscow, Kostroma, and Dubna, and plants at Illertissen, Germany, which was a former Pfizer plant but purchased by R-Pharm in June 2014 and, by agreement, for the first five years will continue to produce Pfizer products,[21] and in Azerbaijan.[19]

R-Pharm gained a large stake in Moscow based Albiogen (Russian: Альбиоген) in 2020.[19] Albiogen specializes in the distribution of foreign high-tech equipment for genetic research.[19] On 23 June 2023, R-Pharm transferred 99% of its stake in Albiogen to A-gen (Russian: А-ген). A-gen is controlled by Andrey Frolov (Russian: Андрей Фролов), who has a majority stake of 50%, and the distributor Alexander Yakovlevsky, who has a minority stake of nearly 50%.[19][22]

COVID-19

[edit]

In 2020, during the COVID-19 outbreak in Russia, the company announced its intention to assist in the mass production of the Sputnik V COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It also announced that it had received a license to manufacture the British Oxford–AstraZeneca COVID-19 vaccine.[23] The company also manufactured the drug Coronavir, which has been described as the first prescription drug specifically developed against COVID-19 to reach the market. It was approved for use in hospitals in July 2020, and in September 2020 it received approval for prescription sales for outpatient use.[7]

In December 2020, R-Pharm and the Gamaleya Research Institute of Epidemiology and Microbiology signed a Memorandum of Understanding with AstraZeneca to collaborate on the development of the COVID-19 vaccine and to conduct joint trials of the British and Russian vaccines.[24]

See also

[edit]

Notes

[edit]
  1. ^ Vladimir Putin's family, especially Katerina Tikhonova, often flies on Alexey Repik's Bombardier Global 5000 (M-FINE)[13]
  2. ^ On 8 February 2023, the Foreign Secretary of the United Kingdom sanctioned numerous entities and individuals including the IT services company Moscoms LLC, the domain LLCInvest.ru, which is hosted by Moscoms LLC through the servers of Moskomsvyaz, and Alexey Repik who had received funding for his R-Pharm from the Russian Direct Investment Fund and had met with Vladimir Putin four times in 2022 as part of Putin's network of wealth and power.[14][15][16][17] After Russia invaded Ukraine in February 2022, Alexey Evgenyevich Repik was placed on Canada's sanctions list on 19 May 2023 as Elites and close associates of the Regime in Russia who provide military technology and know-how to Russia’s armed forces, family members of listed persons, and members of the Kremlin elite.[18]
  3. ^ Founded in 2015, Moscow based Albiogen (Russian: Альбиоген) is the sole distributor of the San Diego based United States company Illumina in Russia, Belarus, Kazakhstan and Uzbekistan.[19] In 2018, Albiogen became a supplier of equipment, consumables and software for DNA nucleotide sequencing of a new generation and analysis on DNA biochips from IDT, Vitrolife, CareDx and Pillar.[19] At the end of 2022, the distributor's revenue fell by 35.75% to 5.4 billion rubles and the company's net profit was 1.35 billion rubles.[19]

References

[edit]
  1. ^ "About company История Компании (History of R-Pharm)". r-pharm.com.[dead link]
  2. ^ "R-Pharm". www.weforum.org. Retrieved 23 June 2021.
  3. ^ "R-Pharm ZAO - Company Profile and News". Bloomberg.com. Retrieved 23 June 2021.
  4. ^ "О КОМПАНИИ ГК «Р-Фарм» – российская высокотехнологичная фармацевтическая компания полного производственного цикла" [ABOUT: R-Pharm Group of Companies is a Russian high-tech pharmaceutical company with a full production cycle]. archive.wikiwix.com. Retrieved 23 June 2021.
  5. ^ "Р-Фарм". www.r-pharm.com. Retrieved 29 November 2023.
  6. ^ "Рейтинг крупнейших компаний России по объему реализации продукции* (archived copy)" [Rating of the largest Russian companies in terms of product sales]. archive.wikiwix.com. Retrieved 23 June 2021.
  7. ^ a b "Russia approves first COVID-19 prescription drug for sale in pharmacies". Reuters. 2020-09-18. Retrieved 2020-09-20.
  8. ^ "Russia approves first COVID-19 prescription drug for sale in pharmacies". Reuters. 18 September 2020. Archived from the original on 18 July 2023. Retrieved 18 July 2023.
  9. ^ "Herbert Smith Freehills advises Mitsui on strategic acquisition of a 10% interest in Russia's R-Pharm". Herbert Smith Freehills | Global law firm. 28 April 2017. Retrieved 28 November 2023.
  10. ^ "Японская Meiji выходит на российский фармацевтический рынок" [Japanese Meiji enters the Russian pharmaceutical market]. Ведомости. 24 March 2012. Retrieved 18 February 2021.
  11. ^ "В Томске открылся научно-образовательный центр подготовки специалистов для фармотрасли" [A scientific and educational center for training specialists for the pharmaceutical industry opened in Tomsk]. 8 November 2012. Retrieved 18 February 2021.
  12. ^ "Покер на госторгах. С кем дружить, чтобы получить миллиарды из бюджета? Владелец "Р-Фарма", главного поставщика лекарств для российских больниц, Алексей Репик — сосед и деловой партнёр бывшего главы Ярославской области Сергея Вахрукова. Последний же был в своё время начальником Игоря Каргаманяна, который сейчас занимает должность первого заместителя министра здравоохранения" [Poker at state auctions. Who to be friends with in order to get billions from the budget? The owner of R-Pharma, the main supplier of medicines for Russian hospitals, Alexei Repik is a neighbor and business partner of the former head of the Yaroslavl region, Sergei Vakhrukov. The latter was at one time the boss of Igor Kargamanyan, who now holds the post of First Deputy Minister of Health.]. Life.ru (in Russian). 13 April 2017. Archived from the original on 18 July 2023. Retrieved 18 July 2023. Alternate archive
  13. ^ Анин, Роман (Anin, Roman) (25 August 2022). "Жизнь семьи Путина за границей — коррупция, балет и армия охранников из спецслужб: «Важные истории» и Der Spiegel получили доступ к уникальному архиву документов сотрудника Службы безопасности президента России. Рассказываем, что мы в нем нашли" [The life of Putin's family abroad - corruption, ballet and an army of security guards from the special services: "Important Stories" and Der Spiegel gained access to a unique archive of documents of an employee of the Security Service of the President of Russia. Here's what we found in it]. iStories«Важные истории» (istories.media) (in Russian). Archived from the original on 18 July 2023. Retrieved 18 July 2023. Alternate archive
  14. ^ "New sanctions target Putin's war machine and financial networks as UK accelerates economic pressure on Russia". gov.uk website. 8 February 2023. Archived from the original on 8 May 2023. Retrieved 18 July 2023.
  15. ^ Blum, Petra; Milling, Palina; Strunz, Benedikt; Felke, Catharina (6 June 2022). "Das Vermögen von Putins Vertrauten: Was besitzt eigentlich Wladimir Putin? Eine öffentlich nicht einsehbare E-Mail-Domain wirft Fragen auf, weil sie Jachten, Paläste, Hotels, Jets und Bankkonten vieler seiner Vertrauten verbindet" [The fortune of Putin's confidants: What does Vladimir Putin actually possess? An email domain that cannot be viewed by the public raises questions because it connects yachts, palaces, hotels, jets and bank accounts of many of his confidants.]. tagesschau.de (in German). Archived from the original on 20 June 2022. Retrieved 18 July 2023.
  16. ^ Дмитриев, Денис (Dmitriev, Denis) ; Шмагун, Олеся (Shmagun, Olesya) ; Патручич, Миранда (Patruchich, Miranda) ; Лозовский, Илья (Lozovsky, Ilya) (20 June 2022). "LLC Invest: еще один кооператив Путина и его друзей Никто не знает, сколько у них денег. Но мы нашли структуру, которая, видимо, помогает им управлять своим богатством. Расследование «Медузы» и OCCRP" [LLC Invest: another cooperative of Putin and his friends No one knows how much money they have. But we have found a structure that apparently helps them manage their wealth. Meduza and OCCRP Investigation]. Meduza.io website (in Russian). Retrieved 18 July 2023.
  17. ^ Shmagun, Olesya; Dmitriev, Denis; Patrucic, Miranda; Lozovsky, Ilya (20 June 2022). "Mysterious Group of Companies Tied to Bank Rossiya Unites Billions of Dollars in Assets Connected to Vladimir Putin". OCCRP. Retrieved 18 July 2023.
  18. ^ "Sanctions – Russian invasion of Ukraine: Canada is imposing new sanctions in response to Russia's unprovoked and unjustified invasion of Ukraine. Canada is imposing sanctions against 17 individuals linked to Russian companies that provide military technology and know-how to Russia's armed forces, family members of listed persons, and members of the Kremlin elite". www.international.gc.ca website. 19 May 2023. Archived from the original on 14 July 2023. Retrieved 18 July 2023.
  19. ^ a b c d e f g h i Ковалева, Анастасия (Kovaleva, Anastasia) (28 June 2023). "«Р-фарм» вышел из капитала дистрибутора зарубежного оборудования для генетических исследований «Альбиоген»: Сделка позволит фармкомпании защитить актив от санкционных ограничений" ["R-Pharm" withdrew from the capital of the distributor of foreign equipment for genetic research "Albiogen": The deal will allow the pharmaceutical company to protect the asset from sanctions restrictions]. Vedomosti (in Russian). Archived from the original on 18 July 2023. Retrieved 18 July 2023.
  20. ^ "Alexey Repik". Forbes. July 2023. Archived from the original on 18 July 2023. Retrieved 18 July 2023.
  21. ^ "Лечить по-русски" [Treat in Russian]. Vedomosti (in Russian). 19 June 2014. Archived from the original on 19 October 2017. Retrieved 18 July 2023.
  22. ^ ""Р-Фарм» вышел из дистрибьютора Illumina «Альбиоген"" ["R-Pharm" left the distributor of Illumina "Albiogen"]. Vademecum (www.vademec.ru) (in Russian). 28 June 2023. Archived from the original on 28 June 2023. Retrieved 18 July 2023.
  23. ^ ""Р-Фарм" договорилась с британской АstraZeneca о производстве вакцины от коронавируса" [R-Pharm has agreed with the British AstraZeneca to produce a vaccine against coronavirus]. 17 July 2020. Retrieved 2021-02-18.
  24. ^ "Путин поздравил Центр Гамалеи, AstraZeneca, РФПИ и "Р-Фарм" с подписанием меморандума" [Putin congratulated the Gamaleya Center, AstraZeneca, RDIF and R-Pharm on signing the memorandum]. 21 December 2020. Retrieved 2021-02-18.
Retrieved from "https://en.wikipedia.org/w/index.php?title=R-Pharm&oldid=1215966811"